5 results about "Seroconversion" patented technology

This invention provides a composite adjuvant, its preparation method, and its application in vaccine preparation, belonging to the field of vaccine adjuvant technology. The composite adjuvant of this invention has low viscosity, only 12 mPa·s at 20°C, ensuring smooth injection; it exhibits high biocompatibility, with no deaths or organ abnormalities in acute toxicity experiments in mice, and no local or systemic adverse reactions or stress responses in chickens after injection; it also demonstrates excellent immunogenicity, achieving a 90% seroconversion rate for Mycoplasma cambogia and an 80% seroconversion rate for Mycoplasma synoviae 28 days after immunization with an inactivated Mycoplasma synoviae vaccine.

The invention relates to the technical field of biological medicine, in particular to fusion protein and application thereof in preparation of products for treating or preventing hepatitis B virus. PreS1 is used as a core antigen component and modified IgM is used as a basic skeleton to obtain a preS1-IgM monomer, then J chain connection is performed to obtain fusion protein, the fusion protein is used as an active component to construct the therapeutic vaccine, anti-preS1 antibody response can be effectively stimulated, and Th1 / Th2 immune response can be synergistically activated. Experiments show that serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model can be remarkably reduced by using the vaccine alone, and serological conversion of part of animals is realized; when the compound is combined with entecavir, the compound shows an excellent synergistic effect. According to the vaccine, the treatment effect is remarkably improved, meanwhile, remarkable liver injury is not caused, and an innovative immunotherapy with prevention and treatment functions is provided for chronic hepatitis B treatment.

The present application relates to the technical field of biological medicine, and particularly relates to a fusion protein and application thereof in preparation of a product for treating or preventing hepatitis B virus. The present application takes preS1 as a core antigen component and takes an improved IgM as a basic skeleton to obtain a preS1-IgM monomer, and then connects the preS1-IgM monomer through a J chain to obtain a fusion protein. The fusion protein is taken as an active component to construct a therapeutic vaccine, which can effectively stimulate an anti-preS1 antibody response and synergistically activate a Th1 / Th2 immune response. Experiments show that the vaccine alone can significantly reduce the serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model, and realize seroconversion of part of the animals. When the vaccine is used in combination with entecavir, a remarkable synergistic effect is exhibited. The vaccine significantly improves the therapeutic effect without causing significant liver damage, and provides an innovative immunotherapy with both prevention and treatment functions for chronic hepatitis B treatment.

The present invention relates to the technical field of vaccine preparation, and particularly, to a bivalent inactivated EV71-CA16 vaccine, a method for preparing the same, and use thereof. The present invention implements the preparation by means of separately adsorbing a monovalent viral stock solution containing an EV71 antigen and a monovalent viral stock solution containing a CA16 antigen with an adjuvant and then mixing same, thereby improving the content of the EV71 antigen and the CA16 antigen in the vaccine substance and greatly improving the adsorption rate and recovery rate of EV71 and CA16 antigens. Moreover, the bivalent EV71-CA16 viral antigen can cause positive seroconversion and up-regulation of the corresponding neutralizing antibody and induce a higher serum antibody level, thus facilitating the preparation of the bivalent inactivated EV71-CA16 vaccine and preventing hand-foot-and-mouth disease.

The invention discloses a traditional Chinese medicine preparation for improving HPV (human papillomavirus) infection symptoms and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 40-60 parts of raw coix seeds, 25-35 parts of oldenlandia diffusa, 15-25 parts of anhydridized bovine beta-lactoglobulin, 8-12 parts of curcumin, 10-20 parts of lentinan, 20-30 parts of astragalus membranaceus, 10-20 parts of radix sophorae flavescentis, 10-20 parts of salvia miltiorrhiza, 20-28 parts of rhizoma smilacis glabrae and 4-8 parts of liquorice. According to the invention, through the charge adsorption effect of the anhydridized bovine beta-lactoglobulin and the HPV capsid protein, the broad-spectrum physical blocking of more than 200 HPV types is realized; the curcumin and the lentinan are combined for use, HPV E6 / E7 gene expression is synchronously inhibited, CD8 + T cell immune clearance is activated, the recurrence rate of viruses in the incubation period is reduced, the astragalus membranaceus and the lentinan cooperate to balance Th1 / Th2 immune response, and immune migration is avoided; the raw coix seeds and the rhizoma smilacis glabrae regulate the pH value and flora balance of a genital tract microenvironment and promote skin damage repair, and all the components have a synergistic effect through a'blocking-inhibiting-clearing-repairing 'quadruple mechanism, so that the clinical negative conversion rate can be increased.